January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
6 citations
,
June 2021 in “EClinicalMedicine” ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.
1 citations
,
April 2025 in “Journal of Cosmetic Dermatology” The serum improves facial skin quality safely and effectively.
55 citations
,
June 2007 in “Journal of Statistical Planning and Inference” The flexible fixed-sequence testing method allows for more effective evaluation of multiple goals in a clinical trial while controlling the risk of false positives.
1 citations
,
November 2025 in “Neuro-Oncology” Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.
Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.
10 citations
,
January 2007 in “Journal of cosmetic and laser therapy” The IPL device is safe, effective, and has high patient satisfaction for hair removal.
August 2024 in “British Journal of Dermatology” Rezpegaldesleukin shows promise for treating severe alopecia areata.
October 2021 in “Dermatology reports” The care model improved timely diagnosis and treatment for psoriasis and psoriatic arthritis.
4 citations
,
November 2018 in “Journal of pharmacological sciences” Mild exercise reduces pain in older rats through a brain chemical, while intense exercise reduces pain in all rats through a different pain-blocking process.
February 2026 in “Trials” The study aims to find the best platelet-rich plasma dose to relieve moderate carpal tunnel syndrome symptoms.
December 2023 in “Trials” The trial is testing if a helmet that uses light can prevent hair loss during chemotherapy.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
Hair regrowth improved, but quality of life did not.
26 citations
,
October 2019 in “JNCI Cancer Spectrum” Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
January 2026 in “Journal of Dermatological Treatment” GT20029 showed some hair growth improvement, but longer studies are needed for better results.
3 citations
,
February 2019 in “Molecular genetics and metabolism” The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.
4 citations
,
September 2024 in “BMC Cancer” Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.
3 citations
,
September 2021 in “EClinicalMedicine” ALRV5XR effectively increases hair density in men with androgenetic alopecia without adverse effects.
294 citations
,
March 2016 in “European journal of cancer” Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.
December 2024 in “Dermatologic Surgery”
4 citations
,
January 2018 in “General Physiology and Biophysics” The steroids allopregnanolone and allotetrahydrodeoxycorticosteron worsened absence seizures in rats.
July 2022 in “British Journal of Dermatology”
2 citations
,
January 2021 in “JAAD Case Reports” Using a special laser and skin medication together successfully cleared a skin condition in a pregnant woman.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
2 citations
,
May 2011 in “Journal of Clinical Oncology” Further testing of paclitaxel poliglumex for this cancer treatment is not justified.
25 citations
,
October 2008 in “Chromatographia” A fast and accurate method was developed to measure alfuzosin and dutasteride in human plasma.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib helps long-term hair regrowth in severe alopecia areata patients.